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Purpose: We aimed to determine the prevalence of anti-cyclic citrullinated pep-
tide (anti-CCP) antibodies in a large group of Korean patients with Behçet’s dis-
ease (BD), with and without joint involvement, and to compare these findings with 
the prevalences of anti-CCP antibodies in patients with rheumatoid arthritis (RA) 
and systemic lupus erythematosus (SLE). Materials and Methods: We tested 189 
patients with BD, 105 with RA, and 36 with SLE for anti-CCP antibodies and IgM 
rheumatoid factor in serum. We reviewed the medical records of patients with BD 
to investigate their personal and clinical characteristics as well as their laboratory 
test results. Results: Anti-CCP antibodies were detected in seven of the 189 BD 
patients (3.7%), at a mean titer of 30.6±44.4 U/mL, in 86 of the 105 RA patients 
(81.9%) with a mean titer of 198.8±205.7 U/mL, and in nine of the 36 SLE pa-
tients (25%) with a mean titer of 180.4±113.9 U/mL. One of the seven anti-CCP-
positive BD patients fulfilled the diagnostic criteria for both BD and RA. Five of 
the seven anti-CCP-positive BD patients (71.4%) had polyarticular joint involve-
ment, and the other two patients (28.6%) had oligoarticular involvement. Conclu-
sion: We determined the prevalence of anti-CCP antibodies in a large group of 
Korean BD patients with and without joint involvement. Negative anti-CCP test in 
patients with BD may help to differentiate BD from RA and SLE, all of which 
present with similar clinical features.
Key Words:    Behçet’s disease, joint involvement, anti-cyclic citrullinated peptide 
antibody, rheumatoid factor, systemic lupus erythematosus, rheuma-
toid arthritis
INTRODUCTION
Citrullination normally occurs in the generation of structural tissues; however, 
pathological accumulation of citrullinated peptides may also be detected at inflam-
mation sites.1 Anti-cyclic citrullinated peptide (anti-CCP) antibodies, which arise 
in response to these peptides, have been detected in several autoimmune or inflam-
matory diseases, including rheumatoid arthritis (RA), psoriatic arthritis, systemic Sung Bin Cho, et al.
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Joint involvement in BD was defined as joint symptoms of 
both arthralgia and arthritis without joint deformities.  
Stored sera were tested for anti-CCP antibodies using a 
second generation Diastat enzyme-linked immunosorbent as-
say, performed according to the manufacturer’s instructions 
and analyzed at the Department of Laboratory Medicine, 
Severance Hospital, Yonsei University College of Medicine, 
Seoul, Korea. IgM RF was measured by the nephelometric 
method (Dade Behring, Marburg, Germany) in the same 
laboratory. Unequivocal readings ≥5 units (U) for the anti-
CCP antibody tests and ≥20 IU/mL for IgM RF were scored 
as positive. 
Frequencies of positive results for the anti-CCP antibody 
and IgM RF tests in the three groups of patients with BD, 
RA, and SLE were compared using the Kruskal-Wallis test, 
with the post hoc Dunn test to isolate differences. The chi-
square test and Fisher’s exact test were applied to test the 
differences in the clinical features of BD patients with or 
without joint involvement. Spearman correlation was used 
to ascertain whether anti-CCP titers were correlated with 
levels of erythrocyte sedimentation rate (ESR) and C-reac-
tive protein (CRP), respectively, in BD patients with anti-
CCP positivity. All of the analyses were performed using 
the Statistical Package for the Social Sciences (SPSS) soft-
ware, version 13.0 (SPSS Inc., Chicago, IL, USA). A p-val-
ue of less than 0.05 was considered statistically significant.
 
RESULTS
 
Results of the anti-CCP antibody and IgM RF tests
Seven of the 189 BD patients (3.7%) had positive anti-CCP 
antibody tests, with a mean titer of 30.6±44.4 U/mL; 86 of 
the 105 RA patients (81.9%) were anti-CCP positive, with a 
mean titer of 198.8±205.7 U/mL; and nine of the 36 SLE pa-
tients (25%) were positive, with a mean titer of 180.4±113.9 
U/mL (Table 1). The differences in anti-CCP positivity be-
tween BD and RA (p<0.0001) and RA and SLE (p<0.0001) 
were statistically significant on the post hoc Dunn test, but 
not BD and SLE (p=0.04). We obtained positive results for 
IgM RF in 36 of the 189 BD patients (19%), with a mean 
IgM RF titer of 101±170 IU/mL; 79 of the 105 RA patients 
(75.2%), with a mean titer of 243.1±504.4 IU/mL; and 16 of 
the 36 SLE patients (44.4%), with a mean titer of 130±215.8 
IU/mL. The differences between BD and RA (p<0.0001), 
BD and SLE (p=0.016), and RA and SLE were statistically 
significant (p=0.006). 
lupus erythematosus (SLE), systemic sclerosis, and idio-
pathic inflammatory myopathy.2-5 
In RA, anti-CCP antibodies are a more reliable diagnos-
tic marker than IgM rheumatoid factor (RF), and may also 
indicate prognoses.1,3,6 Consensus between a positive anti-
CCP antibody test and rheumatoid arthritis has proven to be 
a highly specific diagnostic criterion for RA in patients with 
very early joint symptoms.7 In patients with SLE, anti-CCP 
antibodies are more frequently identified in those with ar-
thritis than in those without arthritis.4 A recent study found 
a significant correlation for anti-CCP antibodies and joint 
symptoms in patients with familial Mediterranean fever.8
Only a few studies, with small groups of patients, have 
reported the frequency of positive anti-CCP antibody tests 
in Behçet’s disease (BD), and the results did not clearly 
correlate with the clinical manifestations of BD.6,9-12 In this 
study, we aimed to determine the prevalence of anti-CCP 
antibodies in a large group of Korean BD patients with and 
without joint involvement and to compare these findings 
with the prevalences of anti-CCP antibodies in patients with 
RA and SLE. 
MATERIALS AND METHODS
　　　
We conducted this retrospective study with approval from 
the Institutional Review Board of Severance Hospital, Yon-
sei University College of Medicine, Seoul, Korea. The study 
included 189 patients registered at the BD Specialty Clinic 
of Severance Hospital (36 males and 153 females with a 
mean age of 44.8 years and age range of 12-69 years) who 
underwent serologic tests for anti-CCP antibody and IgM 
RF. We based our diagnosis of BD on criteria from the In-
ternational Study Group for BD.13 We reviewed the medical 
records of patients with BD for their personal and clinical 
characteristics and laboratory test results, including anti-
CCP antibody and IgM RF tests.
For the same study period, we also enrolled 105 patients 
with RA (29 males and 76 females, with a mean age of 53.4 
years and age range of 18-82 years) and 36 patients with 
SLE (two males and 34 females, with a mean age of 39.4 
years and age range of 16-82 years) who had undergone the 
anti-CCP antibody test. All RA and SLE patients fulfilled 
the revised American College of Rheumatology criteria for 
RA and SLE, respectively.14,15 Available radiographs of BD 
and SLE patients with positive anti-CCP antibody tests 
were reviewed to determine the presence of joint erosions. Anti-CCP and Behçet’s Disease
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years and age range 12-67 years). Among the 140 BD pa-
tients with joint involvement, seven patients (5%; two males 
and five females, mean age 40.3 years and age range 14-58 
years) provided a positive anti-CCP antibody test, while 
none of the 49 patients without arthritis gave a positive test 
(Table 3). The anti-CCP titers in six of the seven anti-CCP-
Clinical characteristics of anti-CCP-positive patients
Among the 189 BD patients, 140 patients (25 males and 115 
females, mean age 44.5 years with an age range of 14-70 
years) showed the symptoms and signs of joint involvement 
(Table 2). The group without articular involvement includ-
ed 49 patients (11 males and 38 females, mean age 45.8 
Table 1. Test Results of Anti-Cyclic Citrullinated Peptide Antibody and IgM Rheumatoid Factor Obtained from Patients with 
Behçet’s Disease (BD), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)
Group No. of subjects No. (%) positive for anti-CCP 
antibody/mean anti-CCP titer (U/mL±SD)
No. (%) positive for IgM 
RF/mean IgM RF titer (IU/mL±SD)
BD patients 189     7 (3.7)/30.6±44.4 36 (19)/101±170
RA patients 105    86 (81.9)/198.8±205.7    79 (75.2)/243.1±504.4
SLE patients   36         9 (25)/180.4±113.9 16 (44.4)/130±215.8
CCP, cyclic citrullinated peptide; RF, rheumatoid factor; SD, standard deviation.
Table 2. Clinical Findings and Results of Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody Tests in Patients with Behçet’s 
Disease (BD) with or without Joint Involvement
Clinical finding
No. (%) of patients with BD
All BD patients BD patients with arthritis BD patients without arthritis
Sex  189 140 49
    Male   36 (19)      25 (17.9)    11 (22.4)
    Female 153 (81)    115 (82.1)    38 (77.6)
Oral ulcer    189 (100)   140 (100)   49 (100)
Genital ulcer    143 (75.7) 105 (75)    38 (77.6)
Eye lesions      38 (20.1)   28 (20)    10 (20.4)
Skin lesions*    158 (83.6) 112 (80)    46 (93.9)
Vascular lesions      6 (3.2)      5 (3.6) 1 (2)
CNS lesions      24 (12.7)   14 (10)    10 (20.4)
GI lesions      61 (32.3)      44 (31.4)    17 (34.7)
Positive for anti-CCP antibody      7 (3.7)   7 (5) 0 (0)
CNS, central nervous system; GI, gastrointestinal tract. 
*BD patients with arthritis vs. BD patients without arthritis, p=0.024.
Table 3. Clinical and Laboratory Features of Seven Patients with Behçet’s Disease (BD) with Positive Anti-Cyclic Citrullinated 
Peptide (Anti-CCP) Antibody Tests
Pt. Sex/Age Anti-CCP titer 
(U/mL)
IgM RF titer 
(IU/mL)
ESR*  
(mm at the first hr)
CRP
† 
(mg/dL)
Site of joint involvement
1 F/47     43.34       23.2 23       0.153 Ankles and wrists 
2 F/46 126.8       28.4 47       0.671
Ankles, knees, metacarpophalangeal joints,   
  proximal interphalangeal joints, sacroiliac 
  joints, shoulders, and wrists
3 F/14       8.23 <20 24 <0.1 Hip, knees, and proximal and distal 
  interphalangeal joints 
4 M/46     13.82   26 96   9.5 Elbow, shoulder, and wrists
5 M/31       5.67 <20 26   2.3 Elbow, feet, and knees
6 F/58     11.36 <20 17       0.193 Cervical spine, elbow, knee, shoulders, and 
  wrists
7 F/40       5.23 <20 27     1.29 Elbow, knee, lower back, and proximal 
  interphalangeal joints
RF, rheumatoid factor; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. 
*Normal range of ESR ≤20 mm at the first hour. 
†Normal range of CRP ≤0.8 mg/dL.Sung Bin Cho, et al.
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Several studies have attempted to establish the frequency 
of positive anti-CCP antibody tests in BD, though findings 
have varied.6,9-12 Kwok, et al.9 reported that one of three BD 
patients had positive anti-CCP tests; while Sghiri, et al.10 re-
ported one among five, and another study reported none in 
four.11 Koca, et al.6 reported that one patient out of 46 BD 
patients (2.2%) and three of the 46 patients (6.5%) tested 
positive for anti-CCP and IgM RF, respectively. The au-
thors suggested that BD may not be associated with anti-
CCP antibodies.6  
In this study, we found that seven of 189 BD patients 
(3.7%) were anti-CCP-positive and 36 of 189 BD patients 
(19%) were IgM RF-positive. Because we found only sev-
en anti-CCP-positive patients, we did not expect a clinical 
comparison of the anti-CCP-positive and negative groups 
to have significance. We did find, however, that all of the 
seven anti-CCP-positive patients had polyarticular or oligo-
articular joint involvement, and that the patient with an anti-
CCP antibody titer over 100 U/mL fulfilled diagnostic crite-
ria for both BD and RA. 
Among 34 patients with SLE, Damián-Abrego, et al.24 
reported positive anti-CCP tests for 7% of those with de-
forming arthropathy, and 5% of those without. The authors 
concluded that anti-CCP antibodies were not correlated 
with lupus arthropathy, regardless of articular deformity. 
Another study reported that eight of 104 SLE patients (8%) 
with or without arthropathy tested positive for anti-CCP an-
tibody, and suggested that anti-CCP-positive SLE patients 
were more likely to have erosive arthritis.25 In comparing 
the prevalence of anti-CCP antibodies in 267 SLE and 76 
RA patients, Qing, et al.4 found that 27.3% of all the SLE 
patients, 42.1% of SLE patients with arthritis and 5.6% of 
SLE patients without arthritis, as well as 85.5% of the RA 
patients were anti-CCP-positive. In our study, nine of the 
36 SLE patients (25%), with or without arthritis, presented 
positive anti-CCP antibody tests, and in six of these patients 
(66.7%), radiography revealed erosive joints. Among our 
anti-CCP-positive BD patients, only one presented minor 
joint erosion, which was assumed not to reflect their anti-
CCP titers.
Previous reports identified citrullinated α-enolase as a po-
tential autoantigen in patients with anti-CCP-positive RA.1,26 
The sera from RA patients reactive to citrullinated α-enolase 
peptide 1 showed cross-reactivity with citrullinated recom-
binant Porphyromonas gingivalis enolase.1 In patients with 
BD, our study group identified α-enolase as a target antigen 
of IgM-type anti-endothelial cell antibodies, and antibodies 
positive BD patients were below 50 U/mL, while one pa-
tient showed a titer greater than 100 U/mL. 
Among the seven anti-CCP-positive BD patients, only 
three also tested positive for IgM RF, with titers of 23.2, 28.4, 
and 20.5 IU/mL. Titers of anti-CCP and ESR as well as anti-
CCP and CRP were not significantly correlated (rho >0.05). 
Five of seven patients (71.4%) showed polyarticular joint 
involvement and the other two (28.6%) showed the oligoar-
ticular type; however, none presented monoarticular in-
volvement. Only one BD patient (patient 5), with anti-CCP 
antibody and IgM RF titers of 5.67 U/mL and <20 IU/mL, 
respectively, had minor joint erosion. Among the nine anti-
CCP-positive SLE patients, four patients (44.4%), with a 
mean anti-CCP titer of 246.4±87.1, had major joint ero-
sions; two patients (22.2%), with a mean titer of 80.9±100.3, 
had minor joint erosions; and three (33.3%), with a mean ti-
ter of 158.6±127, had non-erosive joints. 
Among the 189 BD patients, one patient fulfilled the diag-
nostic criteria for both BD and RA (patient 2) (Table 3).13,14 
This 46-year-old Korean woman had a history of recurrent 
oral and genital ulcerations, erythema nodosum-like skin 
lesions, arthritis, and aseptic meningitis. This patient was 
also diagnosed with RA according to the revised American 
College of Rheumatology criteria for the classification of 
RA.14 Her serum anti-CCP antibody and IgM RF titers 
were 126.8 U/mL and 28.4 IU/mL, respectively. A bone 
scintigraphy revealed multiple uptakes of Tc-99m-hydroxy-
methylene diphosphonate, bilaterally, at the proximal inter-
phalangeal, metacarpophalangeal, wrist, shoulder, sacroili-
ac, knee, and ankle joints. 
DISCUSSION
BD is a chronic multisystemic vasculitis that usually pres-
ents with recurrent oral ulcers, genital ulcers, skin lesions, 
and ocular manifestations. Articular involvement affects be-
tween 5% and 76% of patients with BD,16-22 and approxi-
mately 38% of Korean BD patients.23 Joint symptoms in BD 
patients are usually intermittent, self-limiting and non-ero-
sive, and occur mostly as monoarticular and oligoarticular ar-
thritis.23 The knees and ankles are most commonly involved, 
and arthritis of hand and foot joints, back pain, and erosive 
sacroiliitis are not uncommon. However, the patterns of artic-
ular involvement in BD and RA patients are not distinctively 
different, and the variable occurrence of a positive IgM RF 
test in BD may add to the confusion in diagnosis. Anti-CCP and Behçet’s Disease
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from these patients against human α-enolase cross-reacted 
with an antigen of Streptococcus sanguis that was subse-
quently identified as streptococcal α-enolase.27,28 However, 
serum reactivity to citrullinated α-enolase has not been re-
ported for patients with BD. 
A previous report presented that 1.3% of 286 (132 males 
and 154 females) healthy control subjects were found to be 
positive for anti-CCP antibodies.29 Although our BD study 
group showed a high prevalence of articular involvement, 
compared to the previous multicenter study in Korea,23 only 
3.7% of the patients were anti-CCP-positive, and all of these 
patients except for one had titers below 50 U/mL. More-
over, all of the BD patients without articular involvement 
presented a negative anti-CCP antibody test. We believe 
that our data can be further extended to determine the diag-
nostic value of serum anti-α-enolase and anti-citrullinated 
α-enolase antibodies in BD.
In conclusion, we determined the prevalence of anti-CCP 
antibodies in a large group of Korean patients with BD, 
with and without joint involvement, and compared these 
findings to the prevalence of anti-CCP antibodies in RA and 
SLE. All of the anti-CCP-positive BD patients had polyar-
ticular or oligoarticular involvement, and a high titer of an-
ti-CCP antibodies in a patient with BD may indicate the co-
existence of other rheumatic disorders, especially RA. We 
also suggest that negative results on an anti-CCP antibody 
test in BD may help to distinguish this disease from RA.  
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